Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

CBClaudio G. Brunstein

Discussion

Loading...

Member takes

Overview

Phase 1B/2A study shows safety of DEC and VEN maintenance in myeloid malignancy post allogeneic stem cell transplant, suggesting improved outcomes.

Key Points

  • Weekly maintenance therapy with decitabine and venetoclax improved outcomes in high-risk myeloid malignancies.
  • The trial evaluated one-year relapse-free survival rates compared to historical controls, aiming for better management.
  • Open-label, single-arm Phase 1B/2A study assessing safety and pharmacodynamic effects post allogeneic stem cell transplantation.
  • Results highlight the potential efficacy of this strategy for patients at high risk of disease relapse after transplantation.

Cite This Study

Claudio G. Brunstein (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e52ahttps://doi.org/10.1182/blood-2025-2510
View Full Paper
Ask AI
Bookmark
Share